NEW YORK, March 19, 2018 -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, announced today that the Company will release financial results for the fourth quarter and full year ended December 31, 2017 on Monday, April 2, 2018, before the market opens. Following the release, Dr. Sean Ianchulev, President and Chief Executive Officer, and John Gandolfo, Chief Financial Officer, will host a conference call to review the financial results.
The conference call is scheduled to begin at 8:30 am ET on Monday, April 2, 2018. Participants should dial 1-866-916-2921 (United States) or 1-210-874-7771 (International) with the conference code 3583799. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenoviabio.com.
After the live webcast, the event will be archived on Eyenovia’s website for one year. In addition, a telephonic replay of the call will be available until April 9, 2018. The replay can be accessed by dialing 1-855-859-2056 (United States) or 1-404- 537-3406 (International) with confirmation code 3583799.
About Eyenovia
Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.
Company Contact:
Eyenovia Inc.
John Gandolfo
Chief Financial Officer
[email protected]
Investor Contact:
Tram Bui / Alexander Lobo
The Ruth Group
Phone: 646-536-7035/7037
E-mail: [email protected] / [email protected]
Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
[email protected]


Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Apple Restores Telegram to App Store After Content Policy Violation
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Jetstar to Charge for Overhead Cabin Bags From February
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 



